JP Stock MarketDetailed Quotes

4553 TOWA Pharmaceutical

Watchlist
  • 2817
  • -10-0.35%
20min DelayTrading Nov 18 10:22 JST
145.12BMarket Cap8.57P/E (Static)

TOWA Pharmaceutical Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

TOWA Pharmaceutical H1 FY2025 Earnings Date

Currency：JPYNov 12, 2024

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
Revenue
--
123.40B
--
+14.91%
EPS
--
133.17
--
-5.73%
Analyst Rating
Strong Buy

Nov 16, 2024

TOWA Pharmaceutical Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 3 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: JPY

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q4-- / 71.344B--
--2025/Q3-- / 68.821B--
Nov 12, 20242025/Q260.838B / 59.733B--
Aug 8, 20242025/Q162.566B / 61.500B--
May 14, 20242024/Q459.609B / 61.606B--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q4-- / 71.344B--
--2025/Q3-- / 68.821B--
Nov 12, 20242025/Q260.838B / 59.733B--
Aug 8, 20242025/Q162.566B / 61.500B--
May 14, 20242024/Q459.609B / 61.606B--

Unlock Free Earnings Estimates

TOWA Pharmaceutical Earnings Reports

  • TOWA Pharmaceutical: Confirmation letter

    Nov 13 08:01

  • TOWA Pharmaceutical: Half-Year Report - 69th Term (2024/04/01 - 2025/03/31)

    Nov 13 08:00

  • TOWA Pharmaceutical: Supplementary explanation of financial results for the 2nd quarter (interim period) of the fiscal year ending 2025/3

    Nov 12 14:30

  • TOWA Pharmaceutical: Summary of financial results for the 2nd quarter (interim period) of the fiscal year ending 2025/3 [Japanese GAAP] (consolidated)

    Nov 12 14:30

    • Read more

    Analysis

    Analyst Rating

    Updated: Nov 16, 2024

    Strong Buy

    • Strong Buy

      75.00%

    • Buy

      0.00%

    • Hold

      25.00%

    • Underperform

      0.00%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    JP
    Overall
    Symbol
    Latest Price
    % Chg

    No Data